Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tifacogin

Drug Profile

Tifacogin

Alternative Names: LACI; SC 59735; TFP561; TFPI - Chiron/Pfizer; Tissue factor pathway inhibitor - Chiron/Pfizer

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiron
  • Developer Novartis
  • Class Antithrombotics; Biological proteins
  • Mechanism of Action Factor Xa inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Reperfusion injury; Septic shock; Thrombosis

Most Recent Events

  • 28 Jan 2009 Development discontinued for Community-acquired pneumonia during 2008
  • 22 Apr 2008 Pharmacodynamics data from a preclinical trial against Escherichia coli infection (related to Community-acquired pneumonia) presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008)
  • 22 May 2007 Tifacogin is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top